Abstract:Abstract Background MicroRNAs (miRNAs) represent a class of ∼22nt short non‐coding RNAs that have been identified as a sophisticated layer of post‐transcriptional regulation, governing many cellular, inflammatory and vascular processes. Their biological importance, together with the observation that miRNAs are frequently secreted into the extracellular space and stable in blood serum/plasma and other body fluids, make them specific, robust and non‐invasive biomarkers that could augment the amyloid and tau framework. miRNAs have been used for the detection of prodromal and early Alzheimer’s disease (AD) (e.g., mild cognitive impairment (MCI) due to AD) and to improve the differential diagnosis of AD. However, to date no miRNA panel has been translated into a clinical test. Method In collaboration with the University of Göttingen, the University of Erlangen and Zentralinstitut für Seelische Gesundheit in Mannheim, we prospectively collected PAXgene whole blood from 225 individuals (55‐85 years of age, MMSE ≥20) phenotyped at the respective memory clinics according to state‐of‐the‐art AD diagnostics including CSF core biomarkers. Amyloid positivity as a well validated proxy of brain β‐amyloidosis was determined using a CSF ABeta 42 /ABeta 40 threshold of 0.075. Thus, 127 individuals were ABeta(+) and 96 individuals were ABeta(‐). We deployed 100‐fold cross validation of a linear regression classifier to construct and validate small RNA feature models to evaluate their utility as biomarkers for amyloid positivity and AD diagnosis. Result We generated small RNA feature models and report a median diagnostic receiver operating area under the curve (AUC) of 0.66 (95% CI 0.59‐0.76) for amyloid positivity (ABeta 42 /ABeta 40 < 0.075). We deconvolved our whole blood sRNA signature into their respective plasma or immune cell origin. We found that the predicting features largely originate from the plasma fraction of whole blood (48.8%), marking a significant increase over the unselected distribution of all features (13.1%) of 3.72‐fold (p<0.001). However, several predictive features were found to originate from peripheral immune cells, particularly of the lymphoid arm (CD4+, CD8+ and B‐cells). Conclusion These data suggest the potential of a small RNA‐based blood test as a viable complement to the AT(N) framework for the management of individuals at risk for AD.

Identification of molecular alterations in leukocytes from gene expression profiles of peripheral whole blood of Alzheimer’s disease

A Simple Way to Detect Disease-Associated Cellular Molecular Alterations from Mixed-Cell Blood Samples.

Cellular Transcriptional Alterations of Peripheral Blood in Alzheimer's Disease.

Using blood transcriptome analysis for Alzheimer's disease diagnosis and patient stratification

[Identification of Peripheral Blood GZMK + CD8 + T Cells As Biomarkers of Alzheimer's Disease Based on Single-Cell Transcriptome]

Immune abnormalities and differential gene expression in the hippocampus and peripheral blood of patients with Alzheimer’s disease

Identification of biomarkers of Alzheimer's disease and their characterization of immune function

Common DNA Methylation Alterations of Alzheimer's Disease and Aging in Peripheral Whole Blood

Identification of altered immune cell types and molecular mechanisms in Alzheimer's disease progression by single-cell RNA sequencing

Identification of diagnostic signatures associated with immune infiltration in Alzheimer's disease by integrating bioinformatic analysis and machine-learning strategies

Genes related to neurotransmitter receptors as potential biomarkers for Alzheimer's disease

Identification of potential blood biomarkers for early diagnosis of Alzheimer’s disease through RNA sequencing analysis

Distinctive RNA Expression Profiles in Blood Associated with Alzheimer Disease after Accounting for White Matter Hyperintensities.

Identification of Immune Cells and Key Genes associated with Alzheimer's Disease

Profiling of Serum Exosome MiRNA Reveals the Potential of a MiRNA Panel as Diagnostic Biomarker for Alzheimer’s Disease

Peripheral Blood MicroRNA Expression Profiles in Alzheimer’s Disease: Screening, Validation, Association with Clinical Phenotype and Implications for Molecular Mechanism

Changes in methylation patterns of multiple genes from peripheral blood leucocytes of Alzheimer's disease patients.

Identification of Blood Biomarkers for Alzheimer's Disease Through Computational Prediction and Experimental Validation.

Early Detection of Alzheimer’s Disease using microRNAs

Single-cell RNA sequencing reveals B cell–related molecular biomarkers for Alzheimer’s disease

Functional Genetic Biomarkers of Alzheimer’s Disease and Gene Expression from Peripheral Blood